Using advanced machine learning to improve blood tests for detecting cancer
Advanced machine learning to empower ultra-sensitive liquid biopsy in melanoma and non-small cell lung cancer
This study is looking to improve blood tests that check for cancer signals in people with melanoma and non-small cell lung cancer, using advanced technology to catch things that regular tests might miss, so that doctors can better track how the cancer is doing and adjust treatments sooner for better results.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10881697 on NIH RePORTER |
What this research studies
This research focuses on enhancing the sensitivity of liquid biopsies, which are blood tests that detect circulating tumor DNA (ctDNA) in patients with melanoma and non-small cell lung cancer. By employing whole genome sequencing and advanced machine learning techniques, the study aims to identify cancer signals that are often missed by traditional methods. The goal is to create a more accurate and timely way to monitor cancer progression and response to treatment, potentially allowing for earlier interventions and better patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced melanoma or non-small cell lung cancer who are undergoing treatment.
Not a fit: Patients with early-stage cancers or those not receiving treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective monitoring of cancer treatment, allowing for timely adjustments in therapy and improved patient survival rates.
How similar studies have performed: Previous research has shown promise in using advanced sequencing techniques for liquid biopsies, indicating that this approach could lead to significant advancements in cancer monitoring.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Widman, Adam — Sloan-Kettering Inst Can Research
- Study coordinator: Widman, Adam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.